Industry Satellite Symposiums


Tuesday, November 6th
16:00 - 17:00

INDUSTRY SATELLITE SYMPOSIUM ISANOFI GENZYME + REGENERON
UNLOCKING THE POTENTIAL OF IMMUNO-ONCOLOGY IN ADVANCED CUTANEOUS SQUAMOUS CELL
CARCINOMA (CSCC): ROLE OF CHECKPOINT BLOCKADE


Welcome and introduction Susana Puig
Understanding CSCC – disease overview, epidemiology, risk factors Susana Puig
Existing treatment approaches for the management of advanced CSCC Eggert Stockfleth
Future novel therapeutic strategies, including checkpoint blockade, for advanced CSCC Michael Migden
Q & A Discussion Susana Puig

Conclusions Susana Puig

Wednesday, November 7th
10:30 - 11:30

INDUSTRY SATELLITE SYMPOSIUM   BRISTOL-MYERS SQUIBB

TRANSLATING SCIENCE INTO PROGRESS: THE FUTURE OF MELANOMA TREATMENT?

Chair   Eva Muñoz

 

Welcome and introduction  Eva Muñoz

PD-L1 and beyond: biomarker update  Josep Maria Piulats

Contining innovation - new approaches for melanoma treatment   Christoph Höller

Summary and close  Eva Muñoz

12:45 - 13:45 INDUSTRY SATELLITE LUNCH SYMPOSIUM   HELSINN HEALTHCARE
15:15 - 16:15 INDUSTRY SATELLITE SYMPOSIUM  MSD
18:00 - 19:00 INDUSTRY SATELLITE SYMPOSIUM
Thursday, November 8th
10:30 - 11:30

INDUSTRY SATELLITE SYMPOSIUM AMGEN GmbH

TURNING VIRUSES AGAINST MELANOMA

 

Welcome and introduction Josep Malvehy

Which patients to treat with an intralesional oncolytic virus in melanoma Peter Mohr

Expanding the possibilities for oncolytic viruses with checkpoint inhibitors Olivier Michielin

Future perspectives for oncolytic immunotherapy-panel discussion and Q & A Josep Malvehy

12:45 - 13:45

INDUSTRY SATELLITE LUNCH SYMPOSIUM PIERRE FABRE ONCOLOGY

HOW DO WE IMPROVE TREATMENT OUTCOMES OF PATIENTS WITH BRA-POSITIVE METASTASIC MELANOMA?

Chairs Ana Arance - Axel Hauschild

 

Welcome and introduction Ana Arance, Axel Hauschild

What is new for your patients wirh BRAF-positive metastasic melanoma?  Mario Mandalà

What are your key consderations when choosing targeted therapy to treat patients with BRAF-positive metastasic melanoma? Axel Hauschild

Panel's perspective: an open discussion All (chaired by Ana Arance)

Summary and conclusion Ana Arance, Axel Hauschild

15:15 - 16:15

INDUSTRY SATELLITE SYMPOSIUM NOVARTIS

NEW TREATMENTS, NEW QUESTIONS: PRACTICAL CONSIDERATIONS FOR IMPLEMENTING EFFECTIVE TREATMENT STRATEGIES IN MELANOMA

Secretary

SBC servicios básicos de congresos
Mont-Roig, 13 Atc 2a
08006 Barcelona
Tel. +34 933685538
Fax +34 933685829
www.sbc-congresos.com
info@sbc-congresos.com